These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 33518629)
21. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP; J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562 [TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults. Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Van den Steen P; Cheuvart B; Deraedt Q; Valdes Verelst L; Shamarina D Hum Vaccin Immunother; 2023 Dec; 19(1):2159731. PubMed ID: 36746754 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307 [TBL] [Abstract][Full Text] [Related]
25. Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children. Lee SM; Kim SJ; Chen J; Song R; Kim JH; Devadiga R; Kim YK Hum Vaccin Immunother; 2019; 15(5):1145-1153. PubMed ID: 30668217 [TBL] [Abstract][Full Text] [Related]
26. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ; MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397 [TBL] [Abstract][Full Text] [Related]
27. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282 [TBL] [Abstract][Full Text] [Related]
28. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Asatryan A; Meyer N; Scherbakov M; Romanenko V; Osipova I; Galustyan A; Shamsheva O; Latysheva T; Myasnikova T; Baudson N; Dodet M; Xavier S; Harrington L; Kuznetsova A; Campora L; Van den Steen P Hum Vaccin Immunother; 2021 Mar; 17(3):723-730. PubMed ID: 32845735 [TBL] [Abstract][Full Text] [Related]
29. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223 [TBL] [Abstract][Full Text] [Related]
30. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan. Hara M; Okada K; Yamaguchi Y; Uno S; Otsuka Y; Shimanoe C; Nanri H; Horita M; Ozaki I; Nishida Y; Tanaka K Clin Vaccine Immunol; 2013 Dec; 20(12):1799-804. PubMed ID: 24108779 [TBL] [Abstract][Full Text] [Related]
32. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866 [TBL] [Abstract][Full Text] [Related]
33. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP. Decker MD; Greenberg DP; Johnson DR; Pool V Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919 [TBL] [Abstract][Full Text] [Related]
34. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435 [TBL] [Abstract][Full Text] [Related]
35. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224 [TBL] [Abstract][Full Text] [Related]
36. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985 [TBL] [Abstract][Full Text] [Related]
37. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778 [TBL] [Abstract][Full Text] [Related]
38. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366 [TBL] [Abstract][Full Text] [Related]
39. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777 [TBL] [Abstract][Full Text] [Related]
40. Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents. Hanvatananukul P; Prasarakee C; Sarachai S; Aurpibul L; Sintupat K; Khampan R; Saheng J; Sudjaritruk T Int J Infect Dis; 2020 Jul; 96():422-430. PubMed ID: 32387447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]